Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

This benefit may result from an anti-inflammatory action. Objective: To examine the effect of ACE inhibition on interleukin 6 (IL-6) concentrations after CABG. Patients and methods: 161 patients ...

白细胞介素-6（Interleukin-6，IL-6）家族成员包括IL-6，抑瘤素M（oncostatin M，OSM），白血病抑制因子（Leukemia Inhibitory ...

Privately-held Swiss biotech AB2 Bio has entered into an option and licensing agreement with Japan’s Nippon Shinyaku, which ...

Despite the recent rise in herbal supplement use, research suggests certain supplements may pose risks for patients with autoimmune diseases.

New research reveals a significant reduction in Parkinson’s disease risk among autoimmune patients treated with anti-TNF or ...

Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic ...

(9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by ...